Leichman Lawrence
Aptium Oncology, Comprehensive Cancer at Desert Regional Medical Center, 1180 N. Indian Canyon Drive, Suite E218, Palm Springs, CA 92264, USA.
Surg Oncol Clin N Am. 2007 Jul;16(3):537-56, viii-ix. doi: 10.1016/j.soc.2007.04.003.
As improved surgical techniques allow more patients with CRLM to be operated on with intent to cure, new systemic chemotherapy combinations and regional chemotherapy via the hepatic artery improve disease-free survival. Candidates for complete surgical resection with curative intent should proceed to surgery without neoadjuvant chemotherapy. Postoperative adjuvant therapy is appropriate for those remaining fit with potential for cure. Patients whose liver metastases cannot be resected safely who are otherwise fit for surgery should be treated aggressively with systemic or regional chemotherapy to sufficiently down stage the tumor for surgical resection. Correct timing of surgery, especially with bevacizumab use, has not been established. Without a multidisciplinary team, the potential to cure a select group of patients could be missed.
随着手术技术的改进,更多的结直肠癌肝转移(CRLM)患者能够接受旨在治愈的手术,新的全身化疗方案以及经肝动脉的区域化疗提高了无病生存率。有治愈意向且适合进行完整手术切除的患者应直接进行手术,无需新辅助化疗。术后辅助治疗适用于那些身体状况仍适合且有治愈可能的患者。肝转移灶无法安全切除但其他方面适合手术的患者,应积极接受全身或区域化疗,以使肿瘤充分降期以便进行手术切除。手术的正确时机,尤其是在使用贝伐单抗的情况下,尚未确定。没有多学科团队,可能会错失治愈部分患者的机会。